SRNE - Scilex Holding sees Q3 revenue of 7.2M; top-line data from SP-102 study expected in Q2 2021

Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics (SRNE) announces Q/Q sales growth in ZTlido.Scilex expects Q3 2020 ZTlido net sales to grow 26% to ~$7.2M, compared to $5.7M in Q2-2020. Scilex’s SP-102 (SEMDEXA) is currently being evaluated in Phase 3 clinical trial in the U.S. to evaluate patients with lumbosacral radicular pain/sciatica. Enrollment is anticipated to be completed in Q4 with top-line data expected in Q2 2021. Results from this Phase 3 trial will be used as the basis for licensure application to the FDA.SRNE up 4% premarket.

For further details see:

Scilex Holding sees Q3 revenue of 7.2M; top-line data from SP-102 study expected in Q2 2021